Calm Logic
GLP-1 Specialist

My biggest GLP-1 ethical problem: patients who don’t want to stop
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
www.statnews.com
We’ve gone from weight loss drug shortages to a problem of excess — and eating disorders [archived internal link]
By Jody Dushay, MD
Feb. 19, 2026
...In my experience, people who take GLP-1 therapies fall into several categories.
The majority lose 10% to 20% of their body weight over six to 12 months and keep most of that weight off while continuing treatment; these are average responders.
About 5% do not respond to or tolerate any GLP-1 medication, meaning they have minimal or no weight loss or must stop treatment due to side effects.
Another approximately 5% of my patients are super responders who lose more than 25% of their body weight. I have seen as high as 45%. There are likely genetic underpinnings that explain at least in part why people do not respond or super respond to pharmacologic levels of GLP-1. Right now there are no simple blood tests we can do to predict degree of response.
Everyone eventually reaches a weight loss plateau at the maximum tolerated dose of GLP-1 treatment. And I have had very few people tell me that the plateau weight is their Goldilocks weight. It’s not uncommon for people to become so fixated on seeing a certain number on the scale that they lose sight of having made tremendous improvements in their overall health. Almost everyone wants more weight loss, and I am learning in real time how to best support patients who have reached a weight loss plateau at a weight that is higher than they hoped at the start of treatment. I feel like I’m asking someone who trained for a marathon to feel satisfied after completing 10 kilometers.
But what I am finding the most difficult is how to help people understand why I think they have lost too much weight, and why in some cases I insist on stopping or significantly lowering the dose of their GLP-1 treatment. It’s a really hard negotiation when someone proposes, “How about if I just stay on the same dose for another few months, in case I gain weight on vacation/after menopause/over the holidays?”
As an endocrinologist, I am not professionally trained to treat eating disorders or disordered eating, but I know both when I see them, and I am unfortunately seeing them more often.
GLP-1 therapies are without a doubt life-changing for people with intrusive cravings, nonstop thoughts about food, and a blunted sensation of fullness. At the same time, complete lack of appetite is abnormal and beyond what GLP therapies should do. The same is true about fear of food and fixation on a certain weight. When there is stress at home at mealtime, when friendships are strained because it is uncomfortable to meet socially if food is involved, or when a partner, child, or parent thinks someone has developed very abnormal eating habits, these are all red flags.
Some of my patients minimize the side effects of GLP-1 medication because they don’t want to lower their dose or stop taking it, which can lead to serious complications. Although I do not routinely measure longitudinal change in body composition or bone mass in people taking GLP-1s, mostly because of the cost of DXA scans, significant muscle or bone loss are two objective manifestations of excessive weight loss that should lead to stopping or slowing treatment.
To be sure, I respect that weight loss is a struggle for these patients, and I prescribe and advocate for medication to help people lose weight.
But I am also responsible when a physical or mental health threshold has been crossed. We live in a society where weight is seen as a readout of health, which is as inaccurate as it is unfortunate. Weight and BMI are only one metric of physical and emotional health. Just as important are what a person puts into and does with their body at any weight. The cutoffs for healthy weight based on body mass index (BMI) are plagued by the shortcomings of BMI itself, which should not be used as the only determinant of complicated obesity.
So how do I decide in the moment if a person in front of me is at a healthy weight? I use a collection of objective measurements such as cholesterol levels, blood pressure, waist size, blood sugar, and liver function to support my clinical judgement. I also ask patients what they eat over the course of a typical day, how much physical activity they get, and if they have enough energy to do things they enjoy...
At the start of treatment, I want to understand why a person wants to lose weight, and I avoid setting a numeric weight loss goal. There is such thing as too much weight loss, and I hope this does not become something I see more often as a consequence of GLP-1 therapies.
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
www.statnews.com
We’ve gone from weight loss drug shortages to a problem of excess — and eating disorders [archived internal link]
By Jody Dushay, MD
Feb. 19, 2026
...In my experience, people who take GLP-1 therapies fall into several categories.
The majority lose 10% to 20% of their body weight over six to 12 months and keep most of that weight off while continuing treatment; these are average responders.
About 5% do not respond to or tolerate any GLP-1 medication, meaning they have minimal or no weight loss or must stop treatment due to side effects.
Another approximately 5% of my patients are super responders who lose more than 25% of their body weight. I have seen as high as 45%. There are likely genetic underpinnings that explain at least in part why people do not respond or super respond to pharmacologic levels of GLP-1. Right now there are no simple blood tests we can do to predict degree of response.
Everyone eventually reaches a weight loss plateau at the maximum tolerated dose of GLP-1 treatment. And I have had very few people tell me that the plateau weight is their Goldilocks weight. It’s not uncommon for people to become so fixated on seeing a certain number on the scale that they lose sight of having made tremendous improvements in their overall health. Almost everyone wants more weight loss, and I am learning in real time how to best support patients who have reached a weight loss plateau at a weight that is higher than they hoped at the start of treatment. I feel like I’m asking someone who trained for a marathon to feel satisfied after completing 10 kilometers.
But what I am finding the most difficult is how to help people understand why I think they have lost too much weight, and why in some cases I insist on stopping or significantly lowering the dose of their GLP-1 treatment. It’s a really hard negotiation when someone proposes, “How about if I just stay on the same dose for another few months, in case I gain weight on vacation/after menopause/over the holidays?”
As an endocrinologist, I am not professionally trained to treat eating disorders or disordered eating, but I know both when I see them, and I am unfortunately seeing them more often.
GLP-1 therapies are without a doubt life-changing for people with intrusive cravings, nonstop thoughts about food, and a blunted sensation of fullness. At the same time, complete lack of appetite is abnormal and beyond what GLP therapies should do. The same is true about fear of food and fixation on a certain weight. When there is stress at home at mealtime, when friendships are strained because it is uncomfortable to meet socially if food is involved, or when a partner, child, or parent thinks someone has developed very abnormal eating habits, these are all red flags.
Some of my patients minimize the side effects of GLP-1 medication because they don’t want to lower their dose or stop taking it, which can lead to serious complications. Although I do not routinely measure longitudinal change in body composition or bone mass in people taking GLP-1s, mostly because of the cost of DXA scans, significant muscle or bone loss are two objective manifestations of excessive weight loss that should lead to stopping or slowing treatment.
To be sure, I respect that weight loss is a struggle for these patients, and I prescribe and advocate for medication to help people lose weight.
But I am also responsible when a physical or mental health threshold has been crossed. We live in a society where weight is seen as a readout of health, which is as inaccurate as it is unfortunate. Weight and BMI are only one metric of physical and emotional health. Just as important are what a person puts into and does with their body at any weight. The cutoffs for healthy weight based on body mass index (BMI) are plagued by the shortcomings of BMI itself, which should not be used as the only determinant of complicated obesity.
So how do I decide in the moment if a person in front of me is at a healthy weight? I use a collection of objective measurements such as cholesterol levels, blood pressure, waist size, blood sugar, and liver function to support my clinical judgement. I also ask patients what they eat over the course of a typical day, how much physical activity they get, and if they have enough energy to do things they enjoy...
At the start of treatment, I want to understand why a person wants to lose weight, and I avoid setting a numeric weight loss goal. There is such thing as too much weight loss, and I hope this does not become something I see more often as a consequence of GLP-1 therapies.


